APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Pulmonary Fibrosis Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Pulmonary Fibrosis Drug Market Outlook and Growth Opportunities 2026

Report ID 17402998042 January 2026193 pages

Choose your research edition.

Industry ResearchPulmonary Fibrosis Drug Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Pulmonary Fibrosis Drug Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Pulmonary Fibrosis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pulmonary Fibrosis Drug Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Pulmonary Fibrosis Drug Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Pulmonary Fibrosis Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Pulmonary Fibrosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pulmonary Fibrosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pulmonary Fibrosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Pulmonary Fibrosis Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Pulmonary Fibrosis Drug market include Merck & Co., Inc., Roche, MediciNova, Inc., Genentech, Inc., Galapagos NV, FibroGen, Inc., Cipla Inc., Bristol-Myers Squibb Company and Boehringer Ingelheim, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Pulmonary Fibrosis Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pulmonary Fibrosis Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pulmonary Fibrosis Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pulmonary Fibrosis Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Pulmonary Fibrosis Drug Segment by Company

Merck & Co., Inc.

Roche

MediciNova, Inc.

Genentech, Inc.

Galapagos NV

FibroGen, Inc.

Cipla Inc.

Bristol-Myers Squibb Company

Boehringer Ingelheim

Biogen

Pulmonary Fibrosis Drug Segment by Type

Pirfenidone

Nintedanib

Pulmonary Fibrosis Drug Segment by Application

Hospital

Clinic

Pulmonary Fibrosis Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Pulmonary Fibrosis Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Pulmonary Fibrosis Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pulmonary Fibrosis Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Pulmonary Fibrosis Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Fibrosis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Fibrosis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Fibrosis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pulmonary Fibrosis Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pulmonary Fibrosis Drug industry.

Chapter 3: Detailed analysis of Pulmonary Fibrosis Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Pulmonary Fibrosis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Pulmonary Fibrosis Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pulmonary Fibrosis Drug Industry Trends Table 2. Pulmonary Fibrosis Drug Industry Drivers Table 3. Pulmonary Fibrosis Drug Industry Opportunities and Challenges Table 4. Pulmonary Fibrosis Drug Industry Restraints Table 5. Global Pulmonary Fibrosis Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pulmonary Fibrosis Drug Revenue Share by Company (2021-2026) Table 7. Global Pulmonary Fibrosis Drug Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Pulmonary Fibrosis Drug Sales Volume Share by Company (2021-2026) Table 9. Global Pulmonary Fibrosis Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Pulmonary Fibrosis Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Pulmonary Fibrosis Drug Key Company Manufacturing Base & Headquarters Table 12. Global Pulmonary Fibrosis Drug Company, Product Type & Application Table 13. Global Pulmonary Fibrosis Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Pulmonary Fibrosis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Pirfenidone Table 18. Significant Companies of Nintedanib Table 19. Global Pulmonary Fibrosis Drug Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Pulmonary Fibrosis Drug Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Pulmonary Fibrosis Drug Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Pulmonary Fibrosis Drug Sales Volume Share by Type (2021-2026) Table 23. Global Pulmonary Fibrosis Drug Sales Volume Share by Type (2027-2032) Table 24. Global Pulmonary Fibrosis Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Pulmonary Fibrosis Drug Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Pulmonary Fibrosis Drug Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Pulmonary Fibrosis Drug Sales Value Share by Type (2021-2026) Table 28. Global Pulmonary Fibrosis Drug Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Clinic Table 31. Global Pulmonary Fibrosis Drug Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Pulmonary Fibrosis Drug Sales Volume by Application (2021-2026) & (K Units) Table 33. Global Pulmonary Fibrosis Drug Sales Volume by Application (2027-2032) & (K Units) Table 34. Global Pulmonary Fibrosis Drug Sales Volume Share by Application (2021-2026) Table 35. Global Pulmonary Fibrosis Drug Sales Volume Share by Application (2027-2032) Table 36. Global Pulmonary Fibrosis Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Pulmonary Fibrosis Drug Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Pulmonary Fibrosis Drug Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Pulmonary Fibrosis Drug Sales Value Share by Application (2021-2026) Table 40. Global Pulmonary Fibrosis Drug Sales Value Share by Application (2027-2032) Table 41. Global Pulmonary Fibrosis Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Pulmonary Fibrosis Drug Sales by Region (2021-2026) & (K Units) Table 43. Global Pulmonary Fibrosis Drug Sales Market Share by Region (2021-2026) Table 44. Global Pulmonary Fibrosis Drug Sales by Region (2027-2032) & (K Units) Table 45. Global Pulmonary Fibrosis Drug Sales Market Share by Region (2027-2032) Table 46. Global Pulmonary Fibrosis Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Pulmonary Fibrosis Drug Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Pulmonary Fibrosis Drug Sales Value Share by Region (2021-2026) Table 49. Global Pulmonary Fibrosis Drug Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Pulmonary Fibrosis Drug Sales Value Share by Region (2027-2032) Table 51. Global Pulmonary Fibrosis Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global Pulmonary Fibrosis Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global Pulmonary Fibrosis Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Global Pulmonary Fibrosis Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Pulmonary Fibrosis Drug Sales by Country (2021-2026) & (K Units) Table 56. Global Pulmonary Fibrosis Drug Sales Market Share by Country (2021-2026) Table 57. Global Pulmonary Fibrosis Drug Sales by Country (2027-2032) & (K Units) Table 58. Global Pulmonary Fibrosis Drug Sales Market Share by Country (2027-2032) Table 59. Global Pulmonary Fibrosis Drug Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Pulmonary Fibrosis Drug Sales Value Market Share by Country (2021-2026) Table 61. Global Pulmonary Fibrosis Drug Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Pulmonary Fibrosis Drug Sales Value Market Share by Country (2027-2032) Table 63. Merck & Co., Inc. Company Information Table 64. Merck & Co., Inc. Business Overview Table 65. Merck & Co., Inc. Pulmonary Fibrosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Merck & Co., Inc. Pulmonary Fibrosis Drug Product Portfolio Table 67. Merck & Co., Inc. Recent Development Table 68. Roche Company Information Table 69. Roche Business Overview Table 70. Roche Pulmonary Fibrosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Roche Pulmonary Fibrosis Drug Product Portfolio Table 72. Roche Recent Development Table 73. MediciNova, Inc. Company Information Table 74. MediciNova, Inc. Business Overview Table 75. MediciNova, Inc. Pulmonary Fibrosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. MediciNova, Inc. Pulmonary Fibrosis Drug Product Portfolio Table 77. MediciNova, Inc. Recent Development Table 78. Genentech, Inc. Company Information Table 79. Genentech, Inc. Business Overview Table 80. Genentech, Inc. Pulmonary Fibrosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Genentech, Inc. Pulmonary Fibrosis Drug Product Portfolio Table 82. Genentech, Inc. Recent Development Table 83. Galapagos NV Company Information Table 84. Galapagos NV Business Overview Table 85. Galapagos NV Pulmonary Fibrosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Galapagos NV Pulmonary Fibrosis Drug Product Portfolio Table 87. Galapagos NV Recent Development Table 88. FibroGen, Inc. Company Information Table 89. FibroGen, Inc. Business Overview Table 90. FibroGen, Inc. Pulmonary Fibrosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. FibroGen, Inc. Pulmonary Fibrosis Drug Product Portfolio Table 92. FibroGen, Inc. Recent Development Table 93. Cipla Inc. Company Information Table 94. Cipla Inc. Business Overview Table 95. Cipla Inc. Pulmonary Fibrosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Cipla Inc. Pulmonary Fibrosis Drug Product Portfolio Table 97. Cipla Inc. Recent Development Table 98. Bristol-Myers Squibb Company Company Information Table 99. Bristol-Myers Squibb Company Business Overview Table 100. Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Product Portfolio Table 102. Bristol-Myers Squibb Company Recent Development Table 103. Boehringer Ingelheim Company Information Table 104. Boehringer Ingelheim Business Overview Table 105. Boehringer Ingelheim Pulmonary Fibrosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Boehringer Ingelheim Pulmonary Fibrosis Drug Product Portfolio Table 107. Boehringer Ingelheim Recent Development Table 108. Biogen Company Information Table 109. Biogen Business Overview Table 110. Biogen Pulmonary Fibrosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Biogen Pulmonary Fibrosis Drug Product Portfolio Table 112. Biogen Recent Development Table 113. Key Raw Materials Table 114. Raw Materials Key Suppliers Table 115. Pulmonary Fibrosis Drug Distributors List Table 116. Pulmonary Fibrosis Drug Customers List Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. Pulmonary Fibrosis Drug Product Image Figure 2. Global Pulmonary Fibrosis Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pulmonary Fibrosis Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Pulmonary Fibrosis Drug Sales (2021-2032) & (K Units) Figure 5. Global Pulmonary Fibrosis Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Pulmonary Fibrosis Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Pirfenidone Image Figure 10. Nintedanib Image Figure 11. Global Pulmonary Fibrosis Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Pulmonary Fibrosis Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Pulmonary Fibrosis Drug Sales Volume Share by Type (2021-2032) Figure 14. Global Pulmonary Fibrosis Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Pulmonary Fibrosis Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Pulmonary Fibrosis Drug Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Global Pulmonary Fibrosis Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Pulmonary Fibrosis Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Pulmonary Fibrosis Drug Sales Volume Share by Application (2021-2032) Figure 22. Global Pulmonary Fibrosis Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Pulmonary Fibrosis Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Pulmonary Fibrosis Drug Sales Value Share by Application (2021-2032) Figure 25. Global Pulmonary Fibrosis Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 26. Global Pulmonary Fibrosis Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Pulmonary Fibrosis Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Pulmonary Fibrosis Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Pulmonary Fibrosis Drug Sales Value (2021-2032) & (US$ Million) Figure 30. North America Pulmonary Fibrosis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Pulmonary Fibrosis Drug Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Pulmonary Fibrosis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Pulmonary Fibrosis Drug Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Pulmonary Fibrosis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Pulmonary Fibrosis Drug Sales Value (2021-2032) & (US$ Million) Figure 36. South America Pulmonary Fibrosis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Pulmonary Fibrosis Drug Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Pulmonary Fibrosis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Pulmonary Fibrosis Drug Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Pulmonary Fibrosis Drug Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Pirfenidone
  • Nintedanib
Applications
  • Hospital
  • Clinic
Companies covered
  • Merck & Co., Inc.
  • Roche
  • MediciNova, Inc.
  • Genentech, Inc.
  • Galapagos NV
  • FibroGen, Inc.
  • Cipla Inc.
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim
  • Biogen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Pulmonary Fibrosis Drug Sales Value (2021-2032)
  4. 1.2.2 Global Pulmonary Fibrosis Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Pulmonary Fibrosis Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Pulmonary Fibrosis Drug Market Dynamics
  1. 2.1 Pulmonary Fibrosis Drug Industry Trends
  2. 2.2 Pulmonary Fibrosis Drug Industry Drivers
  3. 2.3 Pulmonary Fibrosis Drug Industry Opportunities and Challenges
  4. 2.4 Pulmonary Fibrosis Drug Industry Restraints
3 Pulmonary Fibrosis Drug Market by Company
  1. 3.1 Global Pulmonary Fibrosis Drug Company Revenue Ranking in 2025
  2. 3.2 Global Pulmonary Fibrosis Drug Revenue by Company (2021-2026)
  3. 3.3 Global Pulmonary Fibrosis Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Pulmonary Fibrosis Drug Average Price by Company (2021-2026)
  5. 3.5 Global Pulmonary Fibrosis Drug Company Ranking (2024-2026)
  6. 3.6 Global Pulmonary Fibrosis Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Pulmonary Fibrosis Drug Company Product Type and Application
  8. 3.8 Global Pulmonary Fibrosis Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Pulmonary Fibrosis Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Pulmonary Fibrosis Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Pulmonary Fibrosis Drug Market by Type
  1. 4.1 Pulmonary Fibrosis Drug Type Introduction
  2. 4.1.1 Pirfenidone
  3. 4.1.2 Nintedanib
  4. 4.2 Global Pulmonary Fibrosis Drug Sales Volume by Type
  5. 4.2.1 Global Pulmonary Fibrosis Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Pulmonary Fibrosis Drug Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Pulmonary Fibrosis Drug Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Pulmonary Fibrosis Drug Sales Value by Type
  9. 4.3.1 Global Pulmonary Fibrosis Drug Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Pulmonary Fibrosis Drug Sales Value by Type (2021-2032)
  11. 4.3.3 Global Pulmonary Fibrosis Drug Sales Value Share by Type (2021-2032)
5 Pulmonary Fibrosis Drug Market by Application
  1. 5.1 Pulmonary Fibrosis Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Pulmonary Fibrosis Drug Sales Volume by Application
  5. 5.2.1 Global Pulmonary Fibrosis Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Pulmonary Fibrosis Drug Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Pulmonary Fibrosis Drug Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Pulmonary Fibrosis Drug Sales Value by Application
  9. 5.3.1 Global Pulmonary Fibrosis Drug Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Pulmonary Fibrosis Drug Sales Value by Application (2021-2032)
  11. 5.3.3 Global Pulmonary Fibrosis Drug Sales Value Share by Application (2021-2032)
6 Pulmonary Fibrosis Drug Regional Sales and Value Analysis
  1. 6.1 Global Pulmonary Fibrosis Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pulmonary Fibrosis Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Pulmonary Fibrosis Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Pulmonary Fibrosis Drug Sales by Region (2027-2032)
  5. 6.3 Global Pulmonary Fibrosis Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Pulmonary Fibrosis Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Pulmonary Fibrosis Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Pulmonary Fibrosis Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Pulmonary Fibrosis Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Pulmonary Fibrosis Drug Sales Value (2021-2032)
  12. 6.6.2 North America Pulmonary Fibrosis Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Pulmonary Fibrosis Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Pulmonary Fibrosis Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Pulmonary Fibrosis Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Pulmonary Fibrosis Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Pulmonary Fibrosis Drug Sales Value (2021-2032)
  21. 6.9.2 South America Pulmonary Fibrosis Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Pulmonary Fibrosis Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Pulmonary Fibrosis Drug Sales Value Share by Country, 2025 VS 2032
7 Pulmonary Fibrosis Drug Country-level Sales and Value Analysis
  1. 7.1 Global Pulmonary Fibrosis Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pulmonary Fibrosis Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Pulmonary Fibrosis Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Pulmonary Fibrosis Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Pulmonary Fibrosis Drug Sales by Country (2027-2032)
  6. 7.4 Global Pulmonary Fibrosis Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Pulmonary Fibrosis Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Pulmonary Fibrosis Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Pulmonary Fibrosis Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Pulmonary Fibrosis Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Pulmonary Fibrosis Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck & Co., Inc.
  2. 8.1.1 Merck & Co., Inc. Company Information
  3. 8.1.2 Merck & Co., Inc. Business Overview
  4. 8.1.3 Merck & Co., Inc. Pulmonary Fibrosis Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Merck & Co., Inc. Pulmonary Fibrosis Drug Product Portfolio
  6. 8.1.5 Merck & Co., Inc. Recent Developments
  7. 8.2 Roche
  8. 8.2.1 Roche Company Information
  9. 8.2.2 Roche Business Overview
  10. 8.2.3 Roche Pulmonary Fibrosis Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Roche Pulmonary Fibrosis Drug Product Portfolio
  12. 8.2.5 Roche Recent Developments
  13. 8.3 MediciNova, Inc.
  14. 8.3.1 MediciNova, Inc. Company Information
  15. 8.3.2 MediciNova, Inc. Business Overview
  16. 8.3.3 MediciNova, Inc. Pulmonary Fibrosis Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 MediciNova, Inc. Pulmonary Fibrosis Drug Product Portfolio
  18. 8.3.5 MediciNova, Inc. Recent Developments
  19. 8.4 Genentech, Inc.
  20. 8.4.1 Genentech, Inc. Company Information
  21. 8.4.2 Genentech, Inc. Business Overview
  22. 8.4.3 Genentech, Inc. Pulmonary Fibrosis Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Genentech, Inc. Pulmonary Fibrosis Drug Product Portfolio
  24. 8.4.5 Genentech, Inc. Recent Developments
  25. 8.5 Galapagos NV
  26. 8.5.1 Galapagos NV Company Information
  27. 8.5.2 Galapagos NV Business Overview
  28. 8.5.3 Galapagos NV Pulmonary Fibrosis Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Galapagos NV Pulmonary Fibrosis Drug Product Portfolio
  30. 8.5.5 Galapagos NV Recent Developments
  31. 8.6 FibroGen, Inc.
  32. 8.6.1 FibroGen, Inc. Company Information
  33. 8.6.2 FibroGen, Inc. Business Overview
  34. 8.6.3 FibroGen, Inc. Pulmonary Fibrosis Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 FibroGen, Inc. Pulmonary Fibrosis Drug Product Portfolio
  36. 8.6.5 FibroGen, Inc. Recent Developments
  37. 8.7 Cipla Inc.
  38. 8.7.1 Cipla Inc. Company Information
  39. 8.7.2 Cipla Inc. Business Overview
  40. 8.7.3 Cipla Inc. Pulmonary Fibrosis Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Cipla Inc. Pulmonary Fibrosis Drug Product Portfolio
  42. 8.7.5 Cipla Inc. Recent Developments
  43. 8.8 Bristol-Myers Squibb Company
  44. 8.8.1 Bristol-Myers Squibb Company Company Information
  45. 8.8.2 Bristol-Myers Squibb Company Business Overview
  46. 8.8.3 Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Product Portfolio
  48. 8.8.5 Bristol-Myers Squibb Company Recent Developments
  49. 8.9 Boehringer Ingelheim
  50. 8.9.1 Boehringer Ingelheim Company Information
  51. 8.9.2 Boehringer Ingelheim Business Overview
  52. 8.9.3 Boehringer Ingelheim Pulmonary Fibrosis Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Boehringer Ingelheim Pulmonary Fibrosis Drug Product Portfolio
  54. 8.9.5 Boehringer Ingelheim Recent Developments
  55. 8.10 Biogen
  56. 8.10.1 Biogen Company Information
  57. 8.10.2 Biogen Business Overview
  58. 8.10.3 Biogen Pulmonary Fibrosis Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Biogen Pulmonary Fibrosis Drug Product Portfolio
  60. 8.10.5 Biogen Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pulmonary Fibrosis Drug Value Chain Analysis
  2. 9.1.1 Pulmonary Fibrosis Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pulmonary Fibrosis Drug Sales Mode & Process
  6. 9.2 Pulmonary Fibrosis Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pulmonary Fibrosis Drug Distributors
  9. 9.2.3 Pulmonary Fibrosis Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst